Bladder Cancer in Black Americans: Blood in Urine

Blood in your urine is the number one warning sign of bladder cancer, and it is the one symptom that decides whether the cancer is caught early or late. The blood may be visible, turning urine pink, red, or the color of cola, or it may show up only on a urine test. It is often painless. It often comes and goes. None of that makes it safe to ignore. For Black Americans, and Black women in particular, a delayed workup of that blood is a leading reason bladder cancer is found at a later, deadlier stage.

Bladder cancer is one of the more common cancers in the United States. The American Cancer Society projects about 84,530 new cases and about 17,870 deaths in 2026. It is more common in men and in older adults; the median age at diagnosis is 73. White Americans are diagnosed with bladder cancer roughly twice as often as Black Americans. That lower incidence does not translate into better outcomes for Black patients. The opposite is true.

Black patients are diagnosed at later stages and survive less often. In a national analysis published in Cancer Medicine in 2023, 76.8 percent of white patients were diagnosed with early-stage bladder cancer compared with 67.8 percent of Black patients, while 6.3 percent of Black patients were diagnosed with metastatic disease compared with 3.3 percent of white patients. Five-year disease-specific survival in an earlier Urology study was 82.8 percent for white patients and 70.2 percent for Black patients, and the gap held even when researchers compared patients at the same stage and tumor grade.

The survival gap is widest for Black women. Across U.S. patients diagnosed with bladder cancer, 5-year survival has been reported at 82 percent for white men, 76 percent for white women, 69 percent for Black men, and 54 percent for Black women, the lowest of any race-sex group. The reason is rooted in how blood in the urine gets handled when a woman reports it.

Bleeding from the bladder gets blamed on a urinary tract infection, on menstruation, or on menopause. Women are treated for a presumed UTI and sent home instead of being referred for the bladder workup the bleeding warrants. The delay shows up in the data. In a national claims study in Cancer, women waited an average of 85 days from their first episode of blood in the urine to a bladder-cancer diagnosis, compared with 74 days for men, and women were more likely to be given a UTI diagnosis first. A separate Medicare analysis found women were less than half as likely as men to get a complete hematuria evaluation. By the time the cancer is found, it is at a higher stage.

Blood in the urine (the medical term is hematuria) is the first sign in most people who have bladder cancer. It behaves in ways that make it easy to dismiss:

• It can be visible or invisible. Enough blood turns the urine pink, orange, red, or cola-colored. Smaller amounts are found only when a urine test shows red blood cells.
• It is usually painless. Early bladder cancer typically causes bleeding with little or no pain.
• It comes and goes. The blood may appear once, clear up, and return weeks later. A single normal urine test does not rule out a problem.

Other symptoms include needing to urinate more often or more urgently, and a burning or painful feeling with urination that does not clear after treatment for an infection. These overlap with a UTI, which is exactly why they get missed.

Smoking is the single biggest cause. It is responsible for about half of all bladder cancers, and people who smoke are at least three times as likely to develop the disease as people who do not. The chemicals from tobacco are filtered by the kidneys, concentrated in the urine, and held against the bladder wall. Quitting lowers the risk over time, which makes it the most powerful thing most people can change.

The other established risks are workplace chemical exposures, especially aromatic amines used in dye, rubber, leather, paint, and metal work, which is why painters, machinists, hairdressers, and firefighters carry higher risk. Chronic bladder infections and irritation, and prior pelvic radiation, also raise risk. Age and male sex raise it too, but none of these change the core rule: blood in the urine gets evaluated regardless of who you are.

The evaluation is straightforward and starts in a doctor's office. A urinalysis confirms and measures the blood. The definitive test is cystoscopy: a urologist passes a thin, lighted scope into the bladder to look directly at the bladder wall. Visible blood in the urine warrants cystoscopy plus imaging of the kidneys and ureters and, in many cases, a urine cytology test that checks for cancer cells. Because the bleeding is intermittent, guidelines from the American Urological Association are explicit that a single later urine test coming back clean does not cancel the need for the workup.

Caught early, bladder cancer is highly treatable. Most cases are non-muscle-invasive at diagnosis and can be removed through the scope, often followed by medicine placed directly into the bladder. The numbers reward early detection: 5-year relative survival is about 73 percent for localized bladder cancer and drops to roughly 10 percent once it has spread to distant sites. The whole disparity story turns on getting to the cystoscopy before the cancer advances.

If you have seen blood in your urine, book an appointment now and name the symptom plainly to the scheduler and the clinician. Ask for a urology referral and a cystoscopy. If you smoke, ask the same visit for help quitting; it is the one risk factor you can act on today. You can find a Black urologist or primary care clinician in our directory who will take blood in the urine seriously the first time you report it. For Black men weighing their own cancer risk, see our guide to prostate cancer in Black men, and for anyone overdue on cancer screening, our piece on colon cancer screening for Black adults.